不同剂量顺铂腹腔灌注联合全身化疗治疗无腹水期卵巢癌的临床观察

Clinical Observation of Different Doses of Cisplatin by Peritoneal Perfusion Combined with Systemic Chemotherapy in the Treatment of Ovarian Cancer without Ascites

目的:观察不同剂量顺铂腹腔灌注联合全身化疗治疗无腹水期卵巢癌的疗效和不良反应。方法:43例无腹水期卵巢癌患者随机分成高剂量组和低剂量组。高剂量组(22例)腹腔灌注顺铂75mg·m-2;低剂量组(21例)腹腔灌注顺铂50mg·m-2。同时配合全身化疗,紫杉醇135mg·m-2,第1天,静脉滴注,每3周重复1次。3周期后评价疗效。结果:高剂量组和低剂量组有效率分别为86.36%和52.38%,2组比较有显著性差异(P<0.05);高剂量组和低剂量组一般状况改善率分别为81.82%和47.62%,2组比较有显著性差异(P<0.05);高剂量组Ⅲ～Ⅳ度恶心、呕吐的发生率达31.82%,高于低剂量组9.52%(P<0.05)。结论:高剂量顺铂腹腔灌注联合全身化疗临床疗效确切,并且可明显改善患者的生存质量,但不良反应发生率较低剂量组高。

OBJECTIVE：To evaluate the clinical efficacy and toxicity of different doses of cisplatin by peritoneal perfusion combined with systemic chemotherapy in the treatment of ovarian cancer without ascites.METHODS：43 cases of ovarian cancer without ascites were randomly divided into high-dose group and low-dose group.Observation group（22 cases）was treated with cisplatin 75 mg · m^-2 and low-dose group（21 cases）was treated with cisplatin 50 mg · m^-2.Both groups were given systemic chemotherapy and taxol 135 mg · m^-2 on the first day via iv every 3 weeks.Clinical efficacies of 2 groups were evaluated after 3 weeks.RESULTS：The effective rates in high-dose group and low-dose group were 86.36%and 52.38%,there were significant differences between 2 groups（P〈0.05）.The improvement rate of symptoms were 81.82% and 47.62%,there were significant differences between 2 groups（P〈0.05）.The incidence of Ⅲ ～Ⅳ degrees of nausea and vomiting in high-dose group and low-dose group were 31.82% and 9.52%（P〈0.05）.CONCLUSION：High-dose of cisplatin by peritoneal perfusion combined with systemic chemotherapy is safe and effective in the treatment of ovarian cancer without ascites and improves the quality of life significantly.Incidence of ADR was higher than low dose group.